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A B S T R A C T
Mammalian sinoatrial node (SAN) cells, the natural pacemaker cells of the heart, 
have an action potential characterized by the presence of a special phase, the slow 
diastolic (pacemaker) depolarization (phase 4), which drives pacemaker activity and 
has therefore attracted the interest of generations of cardiac physiologists. What is the 
basis of the pacemaker depolarization? Here the features of the “funny” (If) current 
of pacemaker cells and its involvement in the generation and autonomic regulation of 
heart rate are briefly addressed. There is also addressed the involvement of If in the 
pharmacological control of cardiac chronotropism, and how defective “funny” chan-
nels can be responsible for inherited heart rhythm disturbances.
I f  G O V E R N S  T H E  G E N E R A T I O N  A N D  A U T O N O M I C 
C O N T R O L  O F  H E A R T  R A T E
In the original report in the sinoatrial node (SAN) in 1979,1 the “funny” If current 
was described as an inward current activated on hyperpolarization in the diastolic 
range of voltages (Fig. 1). Its properties, as well as being relevant to the generation 
of the diastolic depolarization phase of the action potential, were shown to be apt to 
mediate the changes of diastolic depolarization slope, hence of the spontaneous rate, 
caused by ί-receptor stimulation by adrenaline.
Following its early description, much work was devoted to a thorough investiga-
tion of the properties of If in relation to kinetics, ionic nature and modulation by 
neuromediators.2,3 These studies confirmed that the pacemaker current is an essential 
mechanism in the generation of diastolic depolarization and thus in the intiation of the 
heartbeat, but also demonstrated the fundamental role of If in mediating the control 
of cardiac chronotropism by both the sympathetic and parasympathetic autonomic 
inputs.4,5
Which is the mechanism by which If generates spontaneous activity and modulates 
cardiac rate? If is activated by hyperpolarization from a threshold near -40/-50 mV, 
as apparent in Fig. 1a,b; its activation curve (i.e., the degree of current activation at 
steady-state, Fig. 1c) shows that the current activation saturates at about -100/-100 mV, 
demonstrating that the If activation range overlaps that of the diastolic depolarization 
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phase of the action potential (Fig. 1a). As illustrated by plot-
ting the fully-activated I/V relation in Fig. 1c, If is inward at 
diastolic voltages, with a reversal potential near -10/-20 mV, 
which reflects its mixed ionic Na+/K+ permeability.6,7 Since 
the activation range of If overlaps that of diastolic depolariza-
tion (compare panels a and c in Fig. 1), the current activates 
during repolarization of the action potential, and since If is 
inward at diastolic voltages, its activation is a suitable mecha-
nism for the generation of the slowly developing pacemaker 
depolarization.
In addition to generating the diastolic depolarization phase 
of the action potential, hence rhythmic activity, If activation is 
the key process in the modulation of rate by autonomic trans-
mitters. The mammalian pacemaker region (SAN) is densely 
innervated by the autonomic nervous system: sympathetic 
ί-adrenergic stimulation accelerates, and parasympathetic 
muscarinic stimulation slows cardiac rate. When isolated SAN 
cells are superfused with solutions containing low concentra-
tions of autonomic agonists, changes of spontaneous rate are 
characterized by specific changes of the diastolic depolariza-
tion rate, without significant modifications of action potential 
duration and shape (Fig. 2a). This indicates that the process 
responsible for the diastolic depolarization phase of the action 
potential (i.e. If activation) is the primary target of autonomic 
neurotransmitters.
Indeed, the original report of If in SAN cells1 had already 
identified If as a functionally relevant target of adrenergic-
induced positive chronotropic effect. Further experimenta-
tion then showed that ί-adrenergic stimulation increases If 
by displacing its current activation curve to more positive 
voltages, without modifying its conductance (Fig. 2b).4,8 The 
depolarizing shift of If activation curve caused by ί-adrener-
gic stimulation is due to an increased level of intracellular 
FIGURE 1. The “funny” If current. a, spontaneous activity recorded from isolated SAN myocytes reveals a slow diastolic “pace-
maker” depolarization (phase 4 of the action potential) from about -60 to -40 mV. b, If current recorded from a SAN cell during 
hyperpolarizing steps from –35 mV to voltages in the range –45/ –75 mV; the same voltage levels are drawn as broken lines in panel a 
to indicate that the range of If activation overlaps the diastolic depolarization. c, activation curve (left side of y-axis) and I/V relation 
(right side of the y-axis) of If. The activation curve represents the fraction of total current activated at each voltage; the I/V relation 
represents the voltage-dependence of the fully-activated current density, normalized to cell capacity.
FIGURE 2. If mediates the modulation of cardiac rate by the 
autonomic nervous system. a, spontaneous activity recorded 
from a SAN myocyte; activity is accelerated by isoprenaline and 
slowed by acetylcholine, and rate changes do not involve changes 
of action potential shape or duration but are only associated to 
changes in the slope of diastolic depolarization. b, the If activa-
tion curve shifts to the right in the presence of isoprenaline and 
to the left in the presence of acetylcholine, thus increasing and 
decreasing, respectively, the current activated at each voltage; 
these effects are responsible for the changes of diastolic depo-
larization rate shown in panel a. [Modified with permission from 
DiFrancesco, 1993 (a) and Accili et al., 1997 (b)].
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cAMP, which acts as a second messenger in the modulation 
of funny channels.9 This implies that ί-receptor stimulation 
accelerates rate by stimulating adenylate-cyclase activity 
and cAMP synthesis, which shifts the If activation curve to 
more positive voltages and thus increases the inward current 
during diastolic depolarization, ultimately leading to a faster 
depolarization rate.
Later studies showed that If is also strongly dependent 
upon parasympathetic stimulation, by a mechanism which is 
opposite to that elicited by β-adrenergic stimulation.10 It has 
been known for a long time that vagal stimulation releases 
acetylcholine (Ach) and slows cardiac rate, and based on early 
experiments11 it was thought that the mechanism responsible 
for the slowing effect of ACh was an ACh-activated potassium 
current.12 This view was however challenged by the finding 
that ACh strongly inhibits If by shifting its activation curve to 
more negative voltages, an action opposite to that caused by 
catecholamines and due to a muscarinic-induced inhibition of 
adenylate-cyclase and cAMP reduction (Fig. 2a,b).10,13
How could two different mechanisms, both effective to 
slow cardiac rate upon vagal stimulation, operate simultane-
ously? This puzzle was resolved by investigating the ranges 
of ACh concentration required to induce the two effects. We 
showed that while low doses of ACh (up to 0.01-0.03 μM) are 
able to inhibit If and slow the spontaneous frequency of SAN 
cells, much higher concentrations are required to activate the 
potassium conductance; indeed, the ACh dose required for 
half inhibition of If is some 20-fold lower than the dose half 
activating the K+ current.5 This finding introduced a novel con-
cept in cardiac physiology, i.e. that the negative chronotropic 
effect of low-to-moderate vagal stimulatory tone is mediated 
by If inhibition, not by activation of a potassium current.3
P H A R M A C O L O G I C A L  I N H I B I T I O N  O F 
T H E  F U N N Y  C U R R E N T  A N D  R A T E -
R E D U C I N G  A G E N T S
The discovery of If and the detailed investigation of its 
properties were relevant not only in relation to the understand-
ing of the basic principles underlying pacemaker generation 
and modulation, but also in that it provided the possibility to 
implement an approach to pharmacological control of heart 
rate based on the concept of If and its function. Since both 
experimental and mathematical modeling analysis14 have 
clearly established a direct correlation between If and pace-
maker activity, it is to be expected that If inhibition, such as 
the one that can be achieved by f-channel block, can lead to 
slowing of cardiac rate.
Several recently developed drugs able to specifically 
slow heart rate without substantial side-effects (the “heart 
rate-inhibiting” substances) have indeed been shown to act 
by selective blockade of f-channels. These agents may have a 
significant impact on specific cardiac therapies, particularly 
when slowing of heart rate is beneficial, such as chronic angina, 
ischemic heart disease and cardiac failure.15
The slowing action of ivabradine (now in the market with 
the commercial name of Procoralan), and the ivabradine-in-
duced inhibition of If, as recorded in single SAN myocytes, 
are shown in Fig. 3a,b.
At the concentration used in Fig. 3a (0.3 μM), the brady-
cardic action of the drug clearly involves a reduced steepness 
of the diastolic depolarization phase, without substantial 
alterations of either action potential shape or duration. This 
implies that the action of the drug reflects primarily a specific 
inhibition of the funny current. Also, the drug has a “physi-
ological” type of action since it mimics the slowing induced by 
moderate cholinergic activity (compare with Fig. 2a), although 
the mode by which ivabradine inhibits f-channels is complex 
and is quite different from a simple leftward shift of the ac-
tivation curve.16 Block of the f-channels by ivabradine can be 
demonstrated by applying repetitive activating/deactivating 
voltage-clamp protocols during exposure to the drug (Fig. 3b). 
The blocking action of ivabradine on f-channels has been in-
vestigated with some detail.16,17 The data show that ivabradine 
inhibits f-channels with a high degree of specificity relative 
to other channels expressed in the SAN and acts as an “open 
f-channel” blocker, implying that the molecule can reach the 
blocking site within the pore only when channels are open 
FIGURE 3. Ivabradine slows pacemaker rate and blocks f-
channels. a, spontaneous activity recorded from a single SAN 
myocyte is slowed by ivabradine 0.3 μM, through a decreased 
rate of diastolic depolarization. b, ivabradine-induced block of If 
recorded during repetitive activating/deactivating steps (-100/+5 
mV) applied every 6 s from a holding potential of -35 mV.
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during hyperpolarization. At the same time, ivabradine blocks 
f-channels preferentially during depolarization, because it is a 
positively charged molecule. The open-channel block, requir-
ing hyperpolarization, and the preferential block on depolari-
zation are contradictory properties. However, this behaviour is 
the basis of the “use-dependent” action of ivabradine, i.e. the 
requirement of repetitive channel opening/ closing cycles for 
block to develop. This is a useful property because it implies 
that higher degrees of block develop at higher frequencies of 
opening/closing cycles; therefore, the rate-reducing action of 
the drug increases at higher (tachycardic) heart rates, when 
in fact it is more valuable.
Further analysis shows that the blocking action of ivabra-
dine on f-channels differs qualitatively from that of other 
rate-reducing agents such as ZD7288 and zatebradine (UL-
FS49).18,19 Experimental evidence indeed indicates that the 
ivabradine block of If is not simply a voltage-dependent block 
such as that proposed for zatebradine, or a channel state-de-
pendent block as the one proposed for ZD 7288. Rather, the 
ivabradine-induced block of If can be shown to depend on 
the direction of current flow, more than on voltage per se.16 
A possible interpretation of these features is that ivabradine 
block involves a competition between drug molecules and 
permeating Na+ and/or K+ ions for a common binding site 
within the f-channel pore.
R H Y T H M  D I S T U R B A N C E S  A S S O C I A T E D 
T O  F - C H A N N E L  M O D I F I C A T I O N S
As well as physiologically (by the autonomic transmitters) 
and pharmacologically (i.e. by the rate-limiting agents), f-chan-
nel behavior can be altered genetically, by sequence mutations. 
Since HCN channels, the molecular constituents of native f-
channels, were cloned, several structure-function studies have 
thoroughly demonstrated that the normal function of chan-
nels can be modified by alterations of the channel sequence, 
hence of its structure/gating relation.20 This evidence, along 
with the established notion that f-channels are responsible 
for generation and modulation of cardiac rhythm, lead to an 
obvious question: can naturally defective f-channels cause 
rhythm disturbances?
This question has been recently answered by the finding of 
a large Italian family where a specific HCN4 mutation (S672R) 
in the cyclic-nucleotide-binding domain (at the C-terminus) 
leads to inherited sinus bradycardia.21 Of the four known HCN 
isoforms, HCN4 is the most expressed in SAN tissue. In the 
family investigated, each of the bradycardic individuals (rates 
between 43 and 60 bpm, mean of 52.2±1.4 bpm, n=15) carried 
the same HCN4 mutation, while all individuals with normal 
heart rates (range 64 to 81 bpm, mean of 73.2±1.6 bpm) had 
normal HCN4 sequences, indicating tight correlation between 
the HCN4 mutation and the bradycardic phenotype. When 
expressed heterologously in HEK293 cells, mutated channels 
had an activation curve which was shifted to more negative 
voltages relative to wild-type channels (by about 9 mV). When 
identical amounts of wild-type and mutated channel cDNA’s 
were transfected in order to produce heteromeric channels 
such as those occurring in heterozygotes, the HCN4 activa-
tion curve was about 5 mV more negative than that of normal 
channels.21 The mutation thus mimicked the action of a low 
dose of ACh (between 10 and 30 nM) (see Fig. 2b), which can 
fully explain the bradycardic phenotype associated to it.
C O N C L U S I O N
It is well established that the funny current plays an es-
sential role in the generation of the diastolic depolarization 
of cardiac pacemaker cells and in the autonomic modulation 
of heart rate. Recent results show that the relevance of funny 
channels to pacemaker activity applies not only to physi-
ological conditions, but also to pathological conditions, since 
defective channels have been shown to underlie an inherited 
rhythm disturbance such as sinus bradycardia.21
Direct control of cardiac chronotropism can be achieved 
by exploiting the features of funny channels. For example, 
pharmacological control of rate can be achieved by the use of 
drugs such as the funny channel inhibitor ivabradine, which 
reduces in a controlled way the amount of If current during 
diastolic depolarization, and hence heart rate, by selective 
f-channel blockade.16
The properties of funny channels can also be exploited 
to the opposite aim, i.e. to enhance the pacemaker func-
tion. Pacemaker activity, for example, can be transferred to 
quiescent cardiac cells by transfecting HCN channels and/or 
delivering stem cells expressing HCN channels.22 “Biological 
pacemakers” based on the development of the above tech-
niques and exploitation of the properties of funny channels 
may in due time become feasible alternatives to electronic 
pacemakers.
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